Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Deciphera Pharmaceuticals, Inc.
  6. News
  7. Summary
    DCPH   US24344T1016

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
16.41 USD   +4.06%
08/10Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology
BU
08/10Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Study Results in Journal of Clinical Oncology
CI
08/05HC Wainwright Adjusts Price Target on Deciphera Pharmaceuticals to $20 From $15, Reiterates Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q1 Loss $-0.80, vs. Street Est of $-0.88

05/04/2022 | 07:04am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about DECIPHERA PHARMACEUTICALS, INC.
08/10Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Stud..
BU
08/10Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Stud..
CI
08/05HC Wainwright Adjusts Price Target on Deciphera Pharmaceuticals to $20 From $15, Reiter..
MT
08/05JMP Securities Upgrades Deciphera Pharmaceuticals to Market Outperform From Market Perf..
MT
08/04Piper Sandler Adjusts Deciphera Pharmaceuticals Price Target to $13 From $11, Maintains..
MT
08/04Deciphera Pharmaceuticals' Q2 Loss Narrows, Revenue Rises
MT
08/04TRANSCRIPT : Deciphera Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04DECIPHERA PHARMACEUTICALS : Announces Second Quarter 2022 Financial Results - Form 8-K
PU
08/04DECIPHERA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
08/04Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q2 Revenue $32.5M
MT
More news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 129 M - -
Net income 2022 -176 M - -
Net cash 2022 190 M - -
P/E ratio 2022 -6,56x
Yield 2022 -
Capitalization 1 097 M 1 097 M -
EV / Sales 2022 7,01x
EV / Sales 2023 5,84x
Nbr of Employees 280
Free-Float 72,4%
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECIPHERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 16,41 $
Average target price 15,38 $
Spread / Average Target -6,31%
EPS Revisions
Managers and Directors
Steven L. Hoerter President & Chief Executive Officer
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP
James A. Bristol Chairman
Daniel L. Flynn President, Chief Executive Officer & Director
Stephen B. Ruddy Chief Technical Officer & SVP
Sector and Competitors
1st jan.Capi. (M$)
DECIPHERA PHARMACEUTICALS, INC.67.96%1 097
GILEAD SCIENCES, INC.-13.29%78 912
VERTEX PHARMACEUTICALS34.12%75 532
REGENERON PHARMACEUTICALS, INC.-0.45%67 214
WUXI APPTEC CO., LTD.-20.10%40 830
BIONTECH SE-37.80%38 968